TEL AVIV, Israel, June 8, 2021 /PRNewswire/ — EyeYon Medical, an Israeli start-up company developing a variety of ophthalmic products for vision-threatening conditions, announced today that it has ...
The Food and Drug Administration recently approved a new contact lens for the treatment of corneal edema —an eye condition that causes swelling, fluid build up, blurred vision, haziness and scarring.
Please provide your email address to receive an email when new articles are posted on . A polymer film implant attached to the posterior corneal surface can treat corneal edema secondary to ...
GDDs significantly increase corneal edema risk compared to trabeculectomy, with a 27.7% incidence versus 13.5% for trabeculectomy. MIGS and Xen stents show lower risks for corneal edema, with ...
Please provide your email address to receive an email when new articles are posted on . The FDA has accepted an investigational new drug application for EO2002, Emmecell’s lead candidate for the ...
Eyeyon Medical Ltd. has won CE mark approval for its flagship product, Endoart, a synthetic implant that replaces the human endothelium, which the body can’t regenerate. Designed to treat chronic ...
Hazy vision is a symptom of corneal edema secondary to endothelial dysfunction. (Aurion Biotech Image) Aurion Biotech has raised $120 million to advance its cell therapy for an eye disorder that ...
SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (Aurion Biotech), whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today ...
The corneal edema market is projected to witness consistent growth throughout the forecast period (2023–2034). The market size of corneal edema in the US is expected to increase, driven by the launch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results